Real-world Incidence of Intraocular Inflammation Following Intravitreal Faricimab Therapy

CompletedOBSERVATIONAL
Enrollment

6,053

Participants

Timeline

Start Date

November 10, 2024

Primary Completion Date

January 26, 2025

Study Completion Date

March 1, 2025

Conditions
Intraocular Inflammation
Interventions
DRUG

Faricimab Injection [Vabysmo]

The procedures followed local standard protocol, that included the use of 2-3 drops of topical tetracaine anesthesia, use of an eye speculum, topical 5% povidone-iodine disinfection, 33G-needle, injection site 3.5 mm posterior from the limbus marked by calipers in the supertemporal or the inferotemporal quadrant, sterile cotton tip tamponade at the site of injection after removal of the needle, and no post-procedure antibiotics.

Trial Locations (1)

2600

Department of Ophthalmology, Rigshospitalet, Glostrup Municipality

All Listed Sponsors
lead

Rigshospitalet, Denmark

OTHER

NCT06902207 - Real-world Incidence of Intraocular Inflammation Following Intravitreal Faricimab Therapy | Biotech Hunter | Biotech Hunter